All Stories

  1. Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial

    Article • Diabetes Obesity and Metabolism, May 2025, Wiley

    Jelle Beernink

  2. Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians

    Article • Diabetes Obesity and Metabolism, March 2025, Wiley

    Jelle Beernink

  3. Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes

    Article • JAMA Network Open, March 2025, American Medical Association (AMA)

    Jelle Beernink

  4. Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

    Article • Diabetes Care, January 2023, American Diabetes Association

    Jelle Beernink

  5. Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT)

    Article • Frontiers in Pharmacology, July 2022, Frontiers

    Jelle Beernink

  6. Medication adherence in type 2 diabetes patients measured in urine samples

    Article • Diabetes Care, April 2021, American Diabetes Association

    Jelle Beernink, Jelle Beernink